Table 1.
Clinicopathological data of PCa patients.
| Variable | Number of PCa Patients (n = 89) |
|---|---|
| Gleason score 1 | |
| ≤6 | 25 (29.1%) |
| 7 | 47 (54.6%) |
| ≥8 | 14 (16.3%) |
| Missing data | 3 |
| Tumor stage 2 | |
| pT2a | 18 (20.4%) |
| pT2b | 16 (18.2%) |
| pT2c | 16 (18.2%) |
| pT3a | 22 (25.0%) |
| pT3b | 16 (18.2%) |
| Missing data | 1 |
| DRE | |
| Positive | 40 (59.7%) |
| Negative | 27 (40.3%) |
| Missing data | 22 |
| Serum PSA levels | |
| <4 ng/mL | 7 (8.2%) |
| 4–10 ng/mL | 55 (64.7%) |
| ≥10 ng/mL | 23 (27.1%) |
| Missing data | 4 |
| Age | |
| <65 years | 38 (43.7%) |
| 65–74 years | 43 (49.4%) |
| ≥75 years | 6 (6.9%) |
| Missing data | 2 |
1 Gleason score ≤ 6: low-grade cancer; a score of 7: medium-grade cancer; and a score ≥ 8: high-grade cancer. 2 Tumor stage (pT2a: tumor invasion in one half (or less) of one side of prostate; pT2b: tumor involving more than one half of one lobe; pT2c: tumor involving both lobes of prostate gland; pT3a: tumor has broken through capsule; pT3b: tumor extends to pelvic wall and/or causes hydronephrosis or non-functional kidney).